Journal article
Post-marketing experience of vedolizumab in inflammatory bowel disease: analysis of pneumonia and other respiratory tract infections
- Abstract:
-
he annual incidence of pneumonia has been reported as 13.8/1000 in patients with IBD versus 7.6/1000 in healthy subjects (IRR 1.82; 95% CI: 1.75–1.88) [1]. Vedolizumab (VDZ) is a humanised monoclonal antibody that binds to α4β7 integrin, selectively blocking gut-specific lymphocyte trafficking. Gut selectivity may reduce the infection risk compared with anti-tumour necrosis factor-alpha [anti-TNFα] agents, which cause systemic immunosuppression. Here we describe pneumonia and other respirator...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 325.4KB)
-
- Publisher copy:
- 10.1093/ecco-jcc/jjx002.792
Authors
Bibliographic Details
- Publisher:
- Oxford University Press Publisher's website
- Journal:
- Journal of Crohn's and Colitis Journal website
- Volume:
- 11
- Issue:
- S1
- Pages:
- S421–S422
- Publication date:
- 2017-02-01
- Acceptance date:
- 2016-12-15
- DOI:
- ISSN:
-
1873-9946
- Pmid:
-
28172558
- Source identifiers:
-
719788
Item Description
- Pubs id:
-
pubs:719788
- UUID:
-
uuid:d86dbdcc-3b70-4aee-aae4-2c127c727be0
- Local pid:
- pubs:719788
- Deposit date:
- 2017-08-25
Terms of use
- Copyright holder:
- European Crohn’s and Colitis Organisation
- Copyright date:
- 2017
- Notes:
- © 2017 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. This is the accepted manuscript version of the article. The final version is available online from OUP at: 10.1093/ecco-jcc/jjx002.792. This poster was presented at the 12th Congress of ECCO (February 15-18, 2017: Barcelona, Spain).
If you are the owner of this record, you can report an update to it here: Report update to this record